PLPPR4

Summary

PLPPR4 (phospholipid phosphatase related 4, HGNC:23496) is a protein-coding gene on chromosome 1p21.3-p21.2, encoding Phospholipid phosphatase-related protein type 4 (Q7Z2D5). Postsynaptic density membrane protein that indirectly regulates glutamatergic synaptic transmission through lysophosphatidic acid (LPA)-mediated signaling pathways.

The protein encoded by this gene belongs to the lipid phosphate phosphatase (LPP) family. LPPs catalyze the dephosphorylation of a number of bioactive lipid mediators that regulate a variety of cell functions. This protein is specifically expressed in neurons. It is located in the membranes of outgrowing axons and has been shown to be important for axonal outgrowth during development and regenerative sprouting. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 9890 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 47 total
• MANE Select transcript: NM_014839

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23496
Approved symbol	PLPPR4
Name	phospholipid phosphatase related 4
Location	1p21.3-p21.2
Locus type	gene with protein product
Status	Approved
Aliases	PRG-1, LPPR4, KIAA0455, PHP1
Ensembl gene	ENSG00000117600
Ensembl biotype	protein_coding
OMIM	607813
Entrez	9890

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 retained_intron

ENST00000370184, ENST00000370185, ENST00000457765, ENST00000917620, ENST00000917621

RefSeq mRNA: 2 — MANE Select: NM_014839 NM_001166252, NM_014839

CCDS: CCDS53347, CCDS757

Canonical transcript exons

ENST00000370185 — 7 exons

Exon	Start	End
ENSE00000777606	99301724	99301897
ENSE00000777609	99299035	99299230
ENSE00000831248	99300909	99300966
ENSE00001003391	99287965	99288150
ENSE00001067078	99296738	99296867
ENSE00001452020	99305685	99309584
ENSE00001877192	99264492	99264671

Expression profiles

Bgee: expression breadth ubiquitous, 213 present calls, max score 97.63.

FANTOM5 (CAGE): breadth broad, TPM avg 5.4219 / max 385.5303, expressed in 405 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
4166	2.7556	276
4165	1.9345	259
4163	0.6099	104
4167	0.0699	48
4169	0.0351	17
4168	0.0170	10

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
CA1 field of hippocampus	UBERON:0003881	97.63	gold quality
orbitofrontal cortex	UBERON:0004167	96.60	gold quality
entorhinal cortex	UBERON:0002728	95.93	gold quality
Brodmann (1909) area 23	UBERON:0013554	95.60	gold quality
cortical plate	UBERON:0005343	94.64	gold quality
superior frontal gyrus	UBERON:0002661	92.97	gold quality
endothelial cell	CL:0000115	92.81	gold quality
Brodmann (1909) area 46	UBERON:0006483	92.67	gold quality
middle temporal gyrus	UBERON:0002771	91.88	gold quality
prefrontal cortex	UBERON:0000451	91.69	gold quality
frontal pole	UBERON:0002795	90.55	gold quality
parietal lobe	UBERON:0001872	90.51	gold quality
postcentral gyrus	UBERON:0002581	90.51	gold quality
Ammon’s horn	UBERON:0001954	90.43	gold quality
temporal lobe	UBERON:0001871	90.16	gold quality
frontal cortex	UBERON:0001870	89.85	gold quality
primary visual cortex	UBERON:0002436	89.80	gold quality
cerebral cortex	UBERON:0000956	89.78	gold quality
occipital lobe	UBERON:0002021	89.47	gold quality
neocortex	UBERON:0001950	89.23	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	89.11	gold quality
nucleus accumbens	UBERON:0001882	88.94	gold quality
Brodmann (1909) area 9	UBERON:0013540	88.82	gold quality
Brodmann (1909) area 10	UBERON:0013541	88.48	gold quality
telencephalon	UBERON:0001893	88.47	gold quality
lateral nuclear group of thalamus	UBERON:0002736	87.65	gold quality
forebrain	UBERON:0001890	87.61	gold quality
amygdala	UBERON:0001876	86.71	gold quality
cingulate cortex	UBERON:0003027	86.34	gold quality
ventricular zone	UBERON:0003053	86.34	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.20

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

206 targeting PLPPR4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-23B-5P	99.98	66.07	587
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3148	99.97	75.06	6478

Literature-anchored findings (GeneRIF, showing 2)

• Glycosylation as a critical mechanism for PRG-1 function was significantly reduced by the PRG-1R346T SNP glycosylation as a critical mechanism (PMID:26671989)
• PLPPR4 haploinsufficiency causes neurodevelopmental disorders by disrupting synaptic plasticity via mTOR signalling. (PMID:37550884)

Cross-species orthologs

13 orthologs

Organism	Symbol	Gene ID
danio_rerio	plppr4b	ENSDARG00000078755
danio_rerio	plppr4a	ENSDARG00000079671
mus_musculus	Plppr4	ENSMUSG00000044667
rattus_norvegicus	Plppr4	ENSRNOG00000016872
drosophila_melanogaster	wun	FBGN0016078
drosophila_melanogaster	laza	FBGN0037163
drosophila_melanogaster	CG11438	FBGN0037164
drosophila_melanogaster	CG11437	FBGN0037165
drosophila_melanogaster	CG11426	FBGN0037166
drosophila_melanogaster	CG11425	FBGN0037167
drosophila_melanogaster	CG12746	FBGN0037341
drosophila_melanogaster	wun2	FBGN0041087
caenorhabditis_elegans		WBGENE00018756

Paralogs (9): PLPP1 (ENSG00000067113), PLPPR2 (ENSG00000105520), PLPPR5 (ENSG00000117598), PLPPR3 (ENSG00000129951), PLPP2 (ENSG00000141934), PLPP5 (ENSG00000147535), PLPPR1 (ENSG00000148123), PLPP3 (ENSG00000162407), PLPP4 (ENSG00000203805)

Protein

Protein identifiers

Phospholipid phosphatase-related protein type 4 — Q7Z2D5 (reviewed: Q7Z2D5)

Alternative names: Brain-specific phosphatidic acid phosphatase-like protein 1, Inactive 2-lysophosphatidate phosphatase PLPPR4, Lipid phosphate phosphatase-related protein type 4, Plasticity-related gene 1 protein

All UniProt accessions (2): Q7Z2D5, A0AAA9X798

UniProt curated annotations — full annotation on UniProt →

Function. Postsynaptic density membrane protein that indirectly regulates glutamatergic synaptic transmission through lysophosphatidic acid (LPA)-mediated signaling pathways. Binds lysophosphatidic acid (LPA) and mediates its internalization into cells. Could act as receptor or a transporter of this lipid at the post-synaptic membrane. Modulates lysophosphatidic acid (LPA) activity in neuron axonal outgrowth during development by attenuating phospholipid-induced axon collapse.

Subcellular location. Postsynaptic density membrane.

Tissue specificity. Expressed by glutamatergic neurons (at protein level).

Post-translational modifications. O-glycosylated. Probably at Ser-346.

Similarity. Belongs to the PA-phosphatase related phosphoesterase family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q7Z2D5-1	1	yes
Q7Z2D5-2	2
Q7Z2D5-3	3
Q7Z2D5-4	4

RefSeq proteins (2): NP_001159724, NP_055654* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000326	PAP2/HPO	Domain
IPR036938	PAP2/HPO_sf	Homologous_superfamily
IPR043216	PAP-like	Family

Pfam: PF01569

Enzyme classification (BRENDA):

• EC 3.1.3.4 — phosphatidate phosphatase (BRENDA: 31 organisms, 190 substrates, 196 inhibitors, 44 Km, 3 kcat entries)

Substrate kinetics (BRENDA)

10 substrates with measured Km, best-characterized 10. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
PHOSPHATIDIC ACID	0.0054–1.2	17
LYSOPHOSPHATIDATE	0.046–0.179	3
PHOSPHATIDATE	0.284–0.369	3
SPHINGOSINE-1-PHOSPHATE	0.028–0.26	3
CERAMIDE-1-PHOSPHATE	0.022–0.052	2
DIACYLGLYCEROL DIPHOSPHATE	0.041–0.104	2
LYSOPHOSPHATIDIC ACID	0.295–0.58	2
1,2-DIACYL-SN-GLYCEROL-3-PHOSPHATE	0.5954	1
2-(4,4-DIFLUORO-5,7-DIMETHYL-4-BORA-3A,4A-DIAZA-	0.024	1
DIOCTANOYL PHOSPHATIDIC ACID	1.4	1

UniProt features (39 total): glycosylation site 9, modified residue 7, transmembrane region 6, region of interest 4, splice variant 4, sequence variant 4, compositionally biased region 2, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z2D5-F1	56.09	0.19

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 36, 346, 385, 438, 461, 472, 606

Glycosylation sites (9): 214, 219, 268, 362, 432, 455, 513, 543, 568

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-419408	Lysosphingolipid and LPA receptors

MSigDB gene sets: 229 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, GOBP_LIPID_MODIFICATION, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, JAEGER_METASTASIS_DN, GOBP_REGULATION_OF_SYNAPTIC_TRANSMISSION_GLUTAMATERGIC, GOBP_PHOSPHOLIPID_DEPHOSPHORYLATION, TATTATA_MIR374, GOBP_NEUROGENESIS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, MORF_RAD51L3, GOBP_CELL_CELL_SIGNALING, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_EAR_DEVELOPMENT, MORF_CTSB

GO Biological Process (9): phospholipid metabolic process (GO:0006644), signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186), axonogenesis (GO:0007409), inner ear development (GO:0048839), regulation of synaptic transmission, glutamatergic (GO:0051966), regulation of postsynapse organization (GO:0099175), lipid import into cell (GO:0140354), modulation of chemical synaptic transmission (GO:0050804)

GO Molecular Function (1): phosphatidate phosphatase activity (GO:0008195)

GO Cellular Component (7): plasma membrane (GO:0005886), Schaffer collateral - CA1 synapse (GO:0098685), postsynaptic density membrane (GO:0098839), glutamatergic synapse (GO:0098978), membrane (GO:0016020), synapse (GO:0045202), postsynaptic membrane (GO:0045211)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Class A/1 (Rhodopsin-like receptors)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
synapse	2
lipid metabolic process	1
organophosphate metabolic process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
cell morphogenesis involved in neuron differentiation	1
neuron projection morphogenesis	1
axon development	1
ear development	1
anatomical structure development	1
synaptic transmission, glutamatergic	1
modulation of chemical synaptic transmission	1
regulation of synapse organization	1
postsynapse organization	1
lipid transport	1
chemical synaptic transmission	1
regulation of trans-synaptic signaling	1
lipid phosphatase activity	1
membrane	1
cell periphery	1
postsynaptic density	1
postsynaptic membrane	1
postsynaptic specialization membrane	1
cellular anatomical structure	1
cell junction	1
synaptic membrane	1
postsynapse	1

Protein interactions and networks

STRING

1072 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLPPR4	EPHX2	P34913	739
PLPPR4	GNAS	Q5JWF2	570
PLPPR4	MCF2L2	Q86YR7	502
PLPPR4	PTH	P01270	500
PLPPR4	LPAR2	Q9HBW0	448
PLPPR4	SLC38A8	A6NNN8	446
PLPPR4	STX16	O14662	423
PLPPR4	PALMD	Q9NP74	413
PLPPR4	CALM1	P02593	406
PLPPR4	PIP4P2	Q8N4L2	404
PLPPR4	CALML6	Q8TD86	399
PLPPR4	CALML4	Q96GE6	399
PLPPR4	CALML3	P27482	398
PLPPR4	CALML5	Q9NZT1	398
PLPPR4	SPDYE16	A6NNV3	397

IntAct

6 interactions, top by confidence:

A	B	Type	Score
NPAP1	ACACB	psi-mi:“MI:0914”(association)	0.350
DESI1	HRAS	psi-mi:“MI:0914”(association)	0.350
ZNRF3	ITGA8	psi-mi:“MI:0914”(association)	0.350
PLPPR4	FAM91A1	psi-mi:“MI:0914”(association)	0.350
PLPPR1	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350

BioGRID (12): LPPR4 (Two-hybrid), TRIM67 (Affinity Capture-Western), TRIM9 (Affinity Capture-Western), NDUFAF7 (Affinity Capture-MS), FAM91A1 (Affinity Capture-MS), PVRL2 (Affinity Capture-MS), LPPR4 (Affinity Capture-MS), DCAKD (Affinity Capture-MS), LPPR4 (Affinity Capture-MS), MIB2 (Affinity Capture-MS), LPPR4 (Affinity Capture-MS), LPPR4 (Affinity Capture-MS)

ESM2 similar proteins: A0JPH4, A3KGS3, A4IG66, A9ZLX4, F1M8G0, F1Q930, H2MCM1, O17482, O23693, O54828, O95772, P49021, P49805, P86411, Q08DA4, Q17QW2, Q28C33, Q28EW0, Q3B7T1, Q3UD82, Q4QQM5, Q5R9R1, Q5VW38, Q5YLM1, Q5ZKN3, Q66H44, Q6GQV7, Q6WQJ1, Q7Z2D5, Q7ZW11, Q7ZYA0, Q810L4, Q8AVJ1, Q8BKU8, Q8BUV8, Q8BXN9, Q8CB19, Q8IY22, Q8N3A8, Q8N3S3

Diamond homologs: A4II83, Q29RT8, Q32ZL2, Q3SZE3, Q6GM05, Q6GQ62, Q6IQH6, Q6T4P5, Q6W5G4, Q6WAY2, Q7TMB0, Q7TMB7, Q7TME0, Q7TPB0, Q7Z2D5, Q8BFZ2, Q8BJ52, Q8TBJ4, Q8VCY8, Q96GM1, O08564, O14494, O14495, O43688, O88956, P60588, P97544, Q04396, Q0WNG6, Q10022, Q2HJ61, Q3UMZ3, Q54PR7, Q61469, Q8K593, Q8LFD1, Q8NEB5, Q99JY8, Q9DAX2, Q9V576

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

47 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

923 predictions. Top by Δscore:

Variant	Effect	Δscore
1:99287963:A:AG	acceptor_gain	1.0000
1:99287964:G:GG	acceptor_gain	1.0000
1:99296860:A:G	donor_gain	1.0000
1:99299032:TA:T	acceptor_loss	1.0000
1:99299033:A:AG	acceptor_gain	1.0000
1:99299033:A:C	acceptor_loss	1.0000
1:99299034:G:GA	acceptor_loss	1.0000
1:99299034:G:GG	acceptor_gain	1.0000
1:99299034:GGT:G	acceptor_gain	1.0000
1:99299228:CAGG:C	donor_loss	1.0000
1:99299229:AG:A	donor_loss	1.0000
1:99299230:GG:G	donor_loss	1.0000
1:99299231:G:C	donor_loss	1.0000
1:99300903:T:TA	acceptor_gain	1.0000
1:99300907:A:AG	acceptor_gain	1.0000
1:99300908:G:GG	acceptor_gain	1.0000
1:99300908:GA:G	acceptor_gain	1.0000
1:99300908:GAA:G	acceptor_gain	1.0000
1:99300908:GAAA:G	acceptor_gain	1.0000
1:99300964:TCGGT:T	donor_loss	1.0000
1:99300966:GGTA:G	donor_loss	1.0000
1:99300967:G:GG	donor_gain	1.0000
1:99300968:TAA:T	donor_loss	1.0000
1:99301722:A:G	acceptor_gain	1.0000
1:99301723:GAT:G	acceptor_gain	1.0000
1:99301831:G:GG	donor_gain	1.0000
1:99285187:A:G	donor_gain	0.9900
1:99287235:GCAT:G	donor_gain	0.9900
1:99287964:GT:G	acceptor_gain	0.9900
1:99287964:GTT:G	acceptor_gain	0.9900

AlphaMissense

5007 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:99287992:A:C	S84R	1.000
1:99287994:C:A	S84R	1.000
1:99287994:C:G	S84R	1.000
1:99299127:T:C	C211R	1.000
1:99299129:C:G	C211W	1.000
1:99287972:T:A	I77K	0.999
1:99288049:T:A	C103S	0.999
1:99288049:T:C	C103R	0.999
1:99288050:G:A	C103Y	0.999
1:99288050:G:C	C103S	0.999
1:99288051:C:G	C103W	0.999
1:99288121:A:C	S127R	0.999
1:99288123:C:A	S127R	0.999
1:99288123:C:G	S127R	0.999
1:99296861:T:C	F178L	0.999
1:99296863:C:A	F178L	0.999
1:99296863:C:G	F178L	0.999
1:99296867:G:C	G180R	0.999
1:99299050:G:A	G185E	0.999
1:99299127:T:A	C211S	0.999
1:99299128:G:A	C211Y	0.999
1:99299128:G:C	C211S	0.999
1:99299128:G:T	C211F	0.999
1:99299193:T:A	C233S	0.999
1:99299193:T:C	C233R	0.999
1:99299194:G:A	C233Y	0.999
1:99299194:G:C	C233S	0.999
1:99299195:C:G	C233W	0.999
1:99301862:G:C	G311R	0.999
1:99301863:G:A	G311D	0.999

dbSNP variants (sampled 300 via entrez): RS1000103229 (1:99303528 A>G), RS1000172515 (1:99276003 A>T), RS1000181470 (1:99280677 G>A,T), RS1000189052 (1:99286323 T>C), RS1000203556 (1:99276270 G>A,C), RS1000233540 (1:99274658 C>G), RS1000327365 (1:99280164 T>C), RS1000357760 (1:99269935 A>C), RS1000485831 (1:99262956 C>A,T), RS1000539066 (1:99277641 A>C), RS1000610512 (1:99298781 G>A,T), RS1000644348 (1:99286150 A>G), RS1000760631 (1:99271686 T>C), RS1000833060 (1:99270126 A>C), RS1000892240 (1:99265932 G>A)

Disease associations

OMIM: gene MIM:607813 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST001766_3	Non-alcoholic fatty liver disease histology (other)	5.000000e-06
GCST003802_1	Response to citalopram or escitalopram in depression	1.000000e-07
GCST006465_10	Endometrial cancer (endometrioid histology)	4.000000e-07
GCST009733_73	Urinary metabolite levels in chronic kidney disease	2.000000e-12
GCST009735_26	Urinary metabolite modules (eigenmetabolites) in chronic kidney disease	3.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005116	urinary metabolite measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, decreases methylation, increases expression	3
Valproic Acid	increases expression, decreases methylation	3
trichostatin A	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
geldanamycin	increases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	increases expression	1
ferrous chloride	decreases expression	1
triadimefon	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
incobotulinumtoxinA	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cadmium	decreases expression, increases abundance	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	decreases expression	1
Lead	affects expression	1
Mercury	increases expression	1
Methotrexate	decreases expression	1
Tretinoin	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Permethrin	decreases expression	1
Particulate Matter	increases abundance, decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.